Sibylla Biotech core capability PPI-FIT platform (Pharmacological Protein Inactivation by Folding Intermediate Targeting) allows the identification of protein folding intermediates which cannot be addressed using conventional molecular dynamic computing models. These folding intermediates are then “interrogated” through virtual drug screens to generate real chemical hits thus acting on today’s undruggable targets.
Lidia Pieri,
Co-Founder & COO
Giovanni Spagnolli,
Co-Founder & CTO